- Home
- SRTS vs BTAI Comparison
SRTS vs BTAI Comparison
Compare SRTS & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRTS
- BTAI
- Stock Information
- Founded
- SRTS 2010
- BTAI 2017
- Country
- SRTS United States
- BTAI United States
- Employees
- SRTS N/A
- BTAI N/A
- Industry
- SRTS Medical/Dental Instruments
- BTAI Biotechnology: Pharmaceutical Preparations
- Sector
- SRTS Health Care
- BTAI Health Care
- Exchange
- SRTS Nasdaq
- BTAI Nasdaq
- Market Cap
- SRTS 52.9M
- BTAI 48.3M
- IPO Year
- SRTS 2016
- BTAI 2018
- Fundamental
- Price
- SRTS $3.19
- BTAI $2.10
- Analyst Decision
- SRTS Strong Buy
- BTAI Buy
- Analyst Count
- SRTS 3
- BTAI 5
- Target Price
- SRTS $8.00
- BTAI $32.80
- AVG Volume (30 Days)
- SRTS 79.8K
- BTAI 1.0M
- Earning Date
- SRTS 11-06-2025
- BTAI 11-13-2025
- Dividend Yield
- SRTS N/A
- BTAI N/A
- EPS Growth
- SRTS N/A
- BTAI N/A
- EPS
- SRTS N/A
- BTAI N/A
- Revenue
- SRTS $37,564,000.00
- BTAI $868,000.00
- Revenue This Year
- SRTS N/A
- BTAI N/A
- Revenue Next Year
- SRTS $47.33
- BTAI $614.78
- P/E Ratio
- SRTS N/A
- BTAI N/A
- Revenue Growth
- SRTS 3.29
- BTAI N/A
- 52 Week Low
- SRTS $3.03
- BTAI $1.17
- 52 Week High
- SRTS $9.33
- BTAI $13.28
- Technical
- Relative Strength Index (RSI)
- SRTS 43.60
- BTAI 34.29
- Support Level
- SRTS $3.15
- BTAI $2.05
- Resistance Level
- SRTS $3.45
- BTAI $2.46
- Average True Range (ATR)
- SRTS 0.15
- BTAI 0.15
- MACD
- SRTS 0.00
- BTAI -0.00
- Stochastic Oscillator
- SRTS 8.57
- BTAI 2.13
About SRTS Sensus Healthcare Inc.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.